摘要 : Background Leishmania is an intracellular flagellate protozoan parasite that causes a wide range of clinical diseases in humans. The basis of immunological resistance against leishmaniasis depends on Thl reactions and is within th... 展开 Background Leishmania is an intracellular flagellate protozoan parasite that causes a wide range of clinical diseases in humans. The basis of immunological resistance against leishmaniasis depends on Thl reactions and is within the time period of cytokine function. Methods In this study, human anti-IL17 antibody and IFN gamma-producing promastigote were produced to be used in leishmanization. A sequence of light and heavy chains' gene of anti-IL17 antibody and human IFN gamma (hIFN gamma) was obtained from the NCBI database and synthesized in the ECORV reaction site in the plasmid pGH, which it's called pGH-hIFN gamma-antiIL17. The synthesized part using the restriction enzyme ECORV was extracted from the plasmid and after purification by electroporation was transferred to Iranian lizard Leishmania (I.L.L). Evaluation of structural presence in the I.L.L genome at the level of DNA and mRNA was assessed. The expressions of hIFN gamma and anti-IL17 were evaluated and confirmed using ELISA and western blot analysis. The hIFN gamma secreted from the culture medium was collected at high concentrations of 124.36 +/- 6.47 pg/mL. Results Targeted gene replacement into the I.L.L genome was successfully performed for the first time using the pGH-hIFN gamma-antiIL17 plasmid in an identical replacement process. Stabilized recombinant DNA contains a target gene that has no toxicity to the parasite. Conclusions The effective achievement of producing a recombinant gene was done for the first time by replacing the I.L.L-CPC gene with plasmid pGH-hIFN gamma-antiIL17 by targeted gene replacement. This cab can regulate the production of hIFN gamma and anti-IL17. This makes it a viable choice for eliminating leishmania. 收起